Selection of Indications Clause Samples
Selection of Indications. On or before the second anniversary of the Effective Date, Warner shall notify GenVec of any specific indications (other than CAD and PVD) which Warner wishes to retain in the Field. The first indication so selected by Warner shall automatically be included in the Field and Warner's obligation to provide funding for the Research Program and Development shall be increased as set forth in Section 6.3.2
Selection of Indications. The licences granted under Clause 4.1 are limited to the Indications that Oxxon selects in accordance with the provisions of this Clause 4.3, as follows:
(a) Oxxon shall have the exclusive right to select one or more of the Indications, in Field A and/or in Field B, subject to the provisions of the following paragraphs of this Clause 4.
Selection of Indications. The Parties agree that each Product may be effective for the treatment of Indications in the field of [***] diseases, but not limited to, rheumatoid arthritis, COPD, asthma, psoriasis, multiple sclerosis [***] diseases, and that it is in the best interest of both Parties to develop such Product broadly in multiple Indications subject to reasonable commercial and technical considerations. The Parties further agree to pursue a development strategy that initially focuses on the clinical development of the MT203 Product in [***] , and subject to reasonable commercial and technical considerations to expand the Development Plan to include additional Indications following the achievement of clinical proof of principle of such Product in [***] in a clinical trial. To that end, the Parties agree to include in the Development Plan the performance of development activities designed to establish in preclinical models proof of concept of the effectiveness of such Product in two other Indications. Such development activities shall be performed in parallel with the development of the MT203 Product in [***] . If the Parties achieve such preclinical proof of concept with one or more such additional Indications, the Development Plan shall be amended to include the development of the *** Certain information in this document has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. MT203 Product in such additional Indications, subject to reasonable commercial and technical considerations, promptly after the achievement of proof of principle of such Product [***] in a clinical trial.